Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
3.07 ^USD	-1.29%		-6.97%	+0.99%

05-15	Kodiak Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-14	Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy	CI

Kodiak Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 09:01 pm

Kodiak Sciences Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 80.19 million compared to USD 90.63 million a year ago. Basic loss per share from continuing operations was USD 1.53 compared to USD 1.74 a year ago.
For the six months, net loss was USD 150.97 million compared to USD 186.34 million a year ago. Basic loss per share from continuing operations was USD 2.88 compared to USD 3.57 a year ago.

Latest news about Kodiak Sciences Inc.

Kodiak Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy	05-14	CI
Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate Platform	05-02	CI
UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating	04-04	MT
Barclays Raises Price Target on Kodiak Sciences to $3 From $2, Maintains Underweight Rating	04-01	MT
Transcript : Kodiak Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024	03-28
Sector Update: Health Care Stocks Rise Late Afternoon	03-28	MT
Sector Update: Health Care	03-28	MT
Top Midday Decliners	03-28	MT
Kodiak Sciences Shares Tumble After Wider-Than-Expected Q4 Loss	03-28	MT
Kodiak Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Kodiak Sciences Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
Transcript : Kodiak Sciences Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM	01-10
UBS Trims Kodiak Sciences Price Target to $3 From $4, Maintains Neutral Rating	12-21	MT
Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from NASDAQ Biotechnology Index	12-15	CI
North American Morning Briefing : All Eyes on -2-	11-21	DJ
North American Morning Briefing : Stocks Futures -2-	11-20	DJ
Kodiak Sciences' Q3 Loss Narrows	11-14	MT
Kodiak Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Sector Update: Health Care Stocks Gain Late Afternoon	11-06	MT
Sector Update: Health Care	11-06	MT
Kodiak Sciences Share Fall; Company to Resume Tarcocimab Tedromer Eye Drug Development Program	11-06	MT
Kodiak Sciences Inc. Announces Phase 3 Glow Superiority Study Evaluating Tarcocimab Tedromer 5 Mg in Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy	11-06	CI
Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting	11-02	CI
European Midday Briefing : Geopolitical Risks Continue to Drag on Stocks	17/10/23	DJ

Chart Kodiak Sciences Inc.

Duration

Period

More charts

Company Profile

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Sector

Biotechnology & Medical Research

Calendar

04/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.07 USD

Average target price

4.25 USD

Spread / Average Target

+38.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KODIAK SCIENCES INC.	+0.99%	161M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs